<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348335</url>
  </required_header>
  <id_info>
    <org_study_id>32,133</org_study_id>
    <nct_id>NCT00348335</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Cyclosporin for Ocular Rosacea</brief_title>
  <official_title>Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmic Consultants of Long Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ophthalmic Consultants of Long Island</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Restasis (topical cyclosporin) is effective
      in the treatment of ocular rosacea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to compare the efficacy of topical cyclosporin (Restasis) with that of
      Refresh Endura for the treatment of the signs and symptoms of ocular rosacea in patients
      presently controlled on topical corticosteroids
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hyperemia</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>1: Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Refresh Endura</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine 0.05%</intervention_name>
    <arm_group_label>1: Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocular lubricant</intervention_name>
    <arm_group_label>2: Refresh Endura</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient at least 18 years old, but younger than 65

          -  Diagnosis of acne rosacea

          -  Active ocular rosacea based on lid findings of meibomian gland dysfunction with lid
             telangiectasia and hyperemia of at least 2+

          -  Schirmers test of greater than 5mm in at least 1 eye

          -  If patient currently using lid hygiene must maintain regimen during study

          -  Stop oral antibiotics at least 4 weeks prior

        Exclusion Criteria:

          -  Use of topical cyclosporin within last 90 days

          -  Visual acuity of 20/100 or better in both eyes

          -  Pregnant or lactating females

          -  Active ocular infection

          -  Scarring of central cornea

          -  Eyelid defects,abnormal lid positioning or lagophthalmos

          -  Flax seed or Fish oil supplements within last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Wittpenn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2500 Rte 347 Bldg 24</name>
      <address>
        <city>StonyBrook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Eric Donnenfeld</name_title>
    <organization>OCLI</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

